Alpha Cognition enrolls first patient in RESOLVE Phase 4 ZUNVEYL Alzheimer’s study

Alpha Cognition Inc

Alpha Cognition Inc

ACOG

0.00
  • Alpha Cognition enrolled the first patient in RESOLVE, a Phase 4 post-marketing study of ZUNVEYL for mild to moderate Alzheimer’s disease.
  • No results have been presented; topline data is expected after enrollment completes and follow-up ends, with enrollment planned through Q2 2027.
  • The study will assess real-world safety and tolerability, tracking adverse events, treatment persistence, discontinuations, and changes in neuropsychiatric symptoms.
  • RESOLVE is designed to enroll about 150 outpatients across multiple sites, expanding evidence to support ZUNVEYL use in routine clinical practice.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260616546831) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.